Physician profile
Semira Charboneau
NPI 1619975745
$270.71
in general payments reported to CMS, 2019-2025
11 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.64 · 2020: $36.00 · 2022: $12.77 · 2023: $13.66 · 2024: $41.07 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.53 | 2022-2025 | |
| Novo Nordisk INC | $37.05 | 2020-2025 | Wegovy, Saxenda |
| Astrazeneca Pharmaceuticals Lp | $32.89 | 2024-2025 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $28.96 | 2025 | Gemtesa |
| Abbvie INC. | $26.26 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.94 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.54 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.09 | 2020 | |
| Lilly USA, LLC | $15.09 | 2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $13.66 | 2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Semira Charboneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.